| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB, IP |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide from the second quarter of human Caspase 1 protein. |
| Lokalisation |
Cytoplasm, nucleus |
Caspase-1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-3914 |
-
|
| Host |
Mouse |
| Klon |
3CSP03 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
1 ml |
Concentrate |
RUO |
MOB309 |
-
|
| Host |
Mouse |
| Klon |
3CSP03 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
0.1 ml |
Concentrate |
RUO |
MOB309-01 |
-
|
| Host |
Mouse |
| Klon |
3CSP03 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:75 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Cytoplasm |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
3CSP03 |
0.5 ml |
Concentrate |
RUO |
MOB309-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
RUO |
RP096 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
RUO |
RP096-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
(Nuclear), Cytoplasmic |
Caspase-3 (CPP32)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RP096-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Caspase-3, cleaved (CPP32)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK009-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP080 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP080-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, Cell Membrane |
Catenin (beta)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP080-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM13 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
| Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
1 ml |
Concentrate |
CE/IVD |
Z2355ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM13 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
| Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
7 ml |
Ready-to-use |
CE/IVD |
Z2355MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM13 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
| Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
0.5 ml |
Concentrate |
CE/IVD |
Z2355MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM13 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Fibromatosis or transitional cell carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human beta-catenin (CTNNB1) protein |
| Lokalisation |
Membrane, Cytoplasm or Nucleus |
Catenin (beta)
|
Zeta Corporation |
ZM13 |
0.1 ml |
Concentrate |
CE/IVD |
Z2355MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR004 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP004 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP004-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cathepsin D
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP004-05 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
WB, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human lymph node tissue |
| Verdünnung |
20 µg/mL (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Peptide corresponding to amino acids 6 to 20 of human CCR5 |
CCR5 (HIV and Chemokine receptor)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
603-0129 |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3158A |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3158B |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cell membrane, cytoplasm |
CD1a
|
Biocare Medical |
O10 |
6 ml |
Ready-to-use |
CE/IVD |
API3158AA |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
1 ml |
Concentrate |
CE/IVD |
MOB363 |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB363-01 |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB363-05 |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD1a
|
Diagnostic Biosystems |
O10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM173 |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
CD1a |
| Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2096ML |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
CD1a |
| Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2096MP |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
CD1a |
| Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2096MS |
-
|
| Host |
Mouse |
| Klon |
O10 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Skin or Langerhans cell histiocytosis X. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
CD1a |
| Lokalisation |
Cell membrane and Cytoplasm |
CD1a
|
Zeta Corporation |
O10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2096MT |
-
|
| Host |
Rabbit |
| Klon |
SP304 |
| Format |
Concentrate |
| Methode |
IHC-P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human CD2 protein |
| Lokalisation |
Cell membrane |
CD2
|
Zytomed Systems GmbH |
SP304 |
0.1 ml |
Concentrate |
RUO |
503-6040 |
-
|
| Host |
Mouse |
| Klon |
UCHT1 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human infant thymocytes and lymphocytes from a patient with Sezary Syndrome |
CD3
|
Zytomed Systems GmbH |
UCHT1 |
200 µg |
Purified |
RUO |
603-0189 |
-
|
| Host |
Rat |
| Klon |
KT3 |
| Format |
Purified |
| Methode |
F, FL |
| Isotyp |
Rat IgG2a |
CD3
|
Zytomed Systems GmbH |
KT3 |
100 µg |
Purified |
RUO |
603-0191 |
-
|
| Host |
Mouse |
| Klon |
1F4 |
| Format |
Purified |
| Methode |
F, P, IP, FL |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:10 (P) |
| Isotyp |
Mouse IgM |
| Verdünnung |
F344 rat T cells stimulated with PMA (TPA) and calcium ionophore |
CD3
|
Zytomed Systems GmbH |
1F4 |
100 µg |
Purified |
RUO |
603-0193 |
-
|
| Host |
Hamster |
| Klon |
145-2C11 |
| Format |
Purified |
| Methode |
F, P, FL, IP, WB |
| Isotyp |
Hamster IgG |
| Verdünnung |
H-2Kb specific mouse cytoxic T lymphocyte clone BM10-37 |
CD3
|
Zytomed Systems GmbH |
145-2C11 |
250 µg |
Purified |
RUO |
603-2242 |
-
|
| Host |
Mouse |
| Klon |
LN10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane |
CD3
|
Biocare Medical |
LN10 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3152A |
-
|
| Host |
Mouse |
| Klon |
LN10 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane |
CD3
|
Biocare Medical |
LN10 |
1 ml |
Concentrate |
CE/IVD |
ACI3152C |
-
|
| Host |
Mouse |
| Klon |
LN10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane |
CD3
|
Biocare Medical |
LN10 |
6 ml |
Ready-to-use |
CE/IVD |
API3152AA |
-
|
| Host |
Mouse |
| Klon |
LN10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Lokalisation |
Cell membrane |
CD3
|
Biocare Medical |
LN10 |
25 ml |
Ready-to-use |
CE/IVD |
API3152H |
-
|
| Host |
Rabbit |
| Klon |
EP41 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or DIVA |
| Positivkontrolle |
Tonsil, T-cell lymphoma |
| Verdünnung |
1:200 - 1:400 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, some cytoplasmic |
CD3
|
Biocare Medical |
EP41 |
0.1 ml |
Concentrate |
CE/IVD |
CME324A |
-
|
| Host |
Rabbit |
| Klon |
EP41 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or DIVA |
| Positivkontrolle |
Tonsil, T-cell lymphoma |
| Verdünnung |
1:200 - 1:400 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, some cytoplasmic |
CD3
|
Biocare Medical |
EP41 |
0.5 ml |
Concentrate |
CE/IVD |
CME324B |
-
|
| Host |
Rabbit |
| Klon |
EP41 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or DIVA |
| Positivkontrolle |
Tonsil, T-cell lymphoma |
| Verdünnung |
1:200 - 1:400 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, some cytoplasmic |
CD3
|
Biocare Medical |
EP41 |
1 ml |
Concentrate |
CE/IVD |
CME324C |
-
|
| Host |
Mouse |
| Klon |
F7.2.38 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD3
|
Diagnostic Biosystems |
F7.2.38 |
1 ml |
Concentrate |
CE/IVD |
MOB422 |
-
|
| Host |
Mouse |
| Klon |
F7.2.38 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD3
|
Diagnostic Biosystems |
F7.2.38 |
0.1 ml |
Concentrate |
CE/IVD |
MOB422-01 |
-
|
| Host |
Mouse |
| Klon |
F7.2.38 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD3
|
Diagnostic Biosystems |
F7.2.38 |
0.5 ml |
Concentrate |
CE/IVD |
MOB422-05 |
-
|
| Host |
Mouse |
| Klon |
F7.2.38 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD3
|
Diagnostic Biosystems |
F7.2.38 |
6 ml |
ready-to-use |
CE/IVD |
PDM422 |
-
|
| Host |
Rabbit |
| Klon |
EP41 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or DIVA |
| Positivkontrolle |
Tonsil, T-cell lymphoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane, some cytoplasmic |
CD3
|
Biocare Medical |
EP41 |
6 ml |
Ready-to-use |
CE/IVD |
PME324AA |
-
|
| Host |
Mouse |
| Klon |
ZM45 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized human CD3 protein |
| Lokalisation |
Cell membrane |
CD3
|
Zeta Corporation |
ZM45 |
1.0 ml |
Concentrate |
CE/IVD |
Z2352ML |
-
|
| Host |
Mouse |
| Klon |
ZM45 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized human CD3 protein |
| Lokalisation |
Cell membrane |
CD3
|
Zeta Corporation |
ZM45 |
7 ml |
Ready-to-use |
CE/IVD |
Z2352MP |
-
|